Gynecomastia Surgery Cost Calculator
This calculator estimates the real out-of-pocket cost of gynecomastia surgery in Korea. Gynecomastia (여성형유방증, colloquially 여유증; ICD-10 N62, hypertrophy of breast) is enlargement of the male breast, and the Korea Disease Control and Prevention Agency (KDCA) national health information portal describes it as the most common male breast disorder. The calculator takes the tissue composition and Simon grade from your ultrasound report, derives the appropriate surgical method, decides whether the operation passes the coverage gate used in Korean review practice, and then splits the bill: gland excision as an NHIS benefit and liposuction as a non-covered cosmetic item. It reflects private indemnity by policy generation, the annual out-of-pocket ceiling, and the medical expense tax credit, all on 2026 Korean rules.
The defining feature: one operation, two separate bills
Most gynecomastia patients have the mixed type, where glandular and fatty tissue have both developed. Treating it means excising the gland and suctioning the fat in the same sitting. Korean billing then splits that single operation in two: excising glandular tissue is treatment of a disease and is covered by National Health Insurance, while liposuction of fatty tissue is cosmetic surgery and is billed entirely to the patient.
This is what makes gynecomastia different from a typical covered-or-not-covered operation. It is not that the whole surgery is either a benefit or a non-benefit. Two line items on the same operative record land on opposite sides of the line, and they settle under different rules: the covered portion gets the 20 percent inpatient self-pay rate and counts toward the annual out-of-pocket ceiling, while the non-covered portion is paid in full and never counts toward the ceiling.
- Gland excision: NHIS benefit, 20 percent inpatient self-pay, counts toward the ceiling.
- Liposuction: non-covered, 100 percent patient-paid, does not count toward the ceiling.
- Anesthesia, upper-grade room differences, and compression garments are also non-covered.
The three-gate coverage test
Korean review practice requires all three of the following before the operation is accepted as treatment rather than cosmetic surgery. Failing any one of them pushes the entire operation into the non-covered cosmetic category, which also voids private indemnity and the tax credit.
The first gate is tissue: glandular tissue must actually be present. True gynecomastia involves proliferation of breast (glandular) tissue. Pseudogynecomastia is fat accumulation only, so the operation is liposuction alone, which is cosmetic surgery. The second gate is severity: the Simon classification grade must be 2A or higher. The third gate is size: ultrasound must show glandular proliferation of at least 2 cm.
- Gate 1 - tissue: glandular (true) or mixed, not fatty-only (pseudogynecomastia).
- Gate 2 - Simon grade: 2A, 2B, or 3. Grade 1 is treated as not requiring surgery.
- Gate 3 - ultrasound: glandular tissue at least 2 cm.
- Simon 1: slightly enlarged breast with no excess skin - not covered.
- Simon 2A: moderate enlargement without skin sagging - covered.
- Simon 2B: moderate enlargement with skin sagging - covered.
- Simon 3: marked enlargement with skin sagging - covered, and skin excision is added.
Why breast reduction and liposuction are not automatically non-covered
Many people assume breast reduction and liposuction can never be covered in Korea. The statutory text says otherwise. The Rules on the Standards for National Health Insurance Benefits (국민건강보험 요양급여의 기준에 관한 규칙), Annex 2 (Non-Benefit Items, related to Article 9(1)), promulgated and effective 15 April 2026, provides in item 2(a): "cosmetic plastic surgery such as double-eyelid surgery, rhinoplasty (augmentation), breast augmentation or reduction, liposuction, and wrinkle removal, and treatment of its sequelae" - but the whole of item 2 is qualified by the opening clause, "the following medical care where the purpose is NOT the improvement of an essential bodily function."
The operative words are "where the purpose is not the improvement of an essential bodily function." Breast reduction and liposuction are non-covered only when the purpose is cosmetic. Excising glandular tissue to treat the disease of gynecomastia (N62) therefore does not fall within the exclusion and is a benefit. Conversely, suctioning fat where there is no glandular tissue lands squarely within "liposuction ... cosmetic plastic surgery" and is non-covered.
Note an important limitation on precision here: the specific 2 cm and Simon 2A thresholds are not written into any statute, decree, or public notice. A search of the Korean national law information system for administrative rules, court precedents, and statutory interpretations returns no documents for 여성형유방증. Those numbers come from Health Insurance Review and Assessment Service (HIRA) review practice and insurer policy review, and at least four independent Korean sources state them consistently. Final coverage rests on the physician diagnosis and the review outcome.
The 2019 indemnity revision: coverage rescues the liposuction too
In January 2019 the Financial Supervisory Service revised the standard private indemnity (실손의료보험) policy wording. Before the revision, insurers frequently denied the liposuction portion of gynecomastia surgery as cosmetic, precisely because gland excision and liposuction are performed together. After the revision, the policy reimburses "liposuction performed as part of the same series of steps while operating on gynecomastia that qualifies as a benefit under the National Health Insurance Act and related notices." The revision treats liposuction in moderate-or-worse gynecomastia as restorative treatment rather than cosmetic surgery, similar to reconstruction after breast cancer.
This is why passing the coverage gate is worth far more than the benefit discount alone. Clearing the gate does two things at once: the gland excision becomes a benefit at 20 percent self-pay, and the non-covered liposuction becomes indemnity-reimbursable. The calculator surfaces this as a headline "gate delta" - the difference in final cost between passing and failing.
One caveat: the revision is not retroactive. It applies to treatment in progress or newly started after the revision; treatment completed before it cannot be claimed retroactively.
Tissue composition decides the method, not your budget
This calculator deliberately does not let you pick the surgical method. The tissue type determines it, because picking the cheaper operation is the leading cause of reoperation. Korean clinical sources identify the main cause of recurrence as "failing to completely remove both the glandular tissue and the fatty tissue," and recommend excising the gland while suctioning the surrounding fat layer for more complete removal.
The KDCA portal classifies the histology in three ways: glandular (breast tissue only), fatty-glandular (described as "the most common form," with glandular and fatty tissue developed together), and fatty (fat only). Glandular tissue is firm and cannot be removed by liposuction, so excision is mandatory; conversely, excision alone in a mixed case leaves fat behind or produces a crater-like depression.
- Glandular type: gland excision alone (direct excision through an areolar incision, or the pull-out method).
- Fatty-glandular (mixed, most common): combined gland excision plus liposuction.
- Fatty type (pseudogynecomastia): liposuction alone - cosmetic, non-covered.
- Simon grade 3: skin excision (lift) is added, raising cost by a step.
What it actually costs
When the gate is passed, Korean clinics report an out-of-pocket amount of roughly KRW 500,000 to 900,000 for the covered portion of true gynecomastia surgery. That is consistent with the statutory 20 percent inpatient self-pay applied to a covered total in the KRW 2,500,000 to 4,500,000 range. The Enforcement Decree of the National Health Insurance Act, Annex 2 (Rates and Amounts of Co-payment, related to Article 19(1)), item 1(a)(1), sets inpatient co-payment at "20/100 of the total medical care benefit cost ... plus 50/100 of meal charges during hospitalization." Day surgery is billed at the outpatient rate instead, which runs 30 to 60 percent by hospital level.
Non-covered pricing has no standard schedule because clinics set it themselves. Observed 2026 market ranges are roughly KRW 1,200,000-2,500,000 for the fatty type, KRW 2,500,000-4,500,000 for the glandular type, KRW 3,000,000-5,500,000 for the mixed type, and KRW 4,500,000-7,000,000 when skin excision is needed for Simon grade 3. Some guides quote lower bands (about KRW 1,000,000-1,500,000 for pseudogynecomastia and KRW 1,500,000-2,500,000 for true gynecomastia). Patient reports put the realistic all-in figure at KRW 2,000,000-4,000,000 without indemnity, and about KRW 1,000,000 with it.
Be skeptical of headline pricing. Platform "one-day gynecomastia" event prices in the KRW 400,000-800,000 range often mix in non-surgical injection treatments, or exclude anesthesia, compression garments, and aftercare. The same clinic will frequently advertise both an event price and a KRW 3,300,000-5,500,000 combined-procedure price. Compare total written quotes, not advertised starting prices.
- Covered portion (gate passed): roughly KRW 500,000-900,000 out of pocket.
- Inpatient benefit self-pay: 20 percent. Day surgery outpatient: 30-60 percent by hospital level.
- Non-covered mixed-type quote: roughly KRW 3,000,000-5,500,000 before indemnity.
- Regional price multipliers are an assumption: no public data quantifies Seoul-versus-provincial gynecomastia pricing.
Indemnity, the ceiling, and the tax credit
Private indemnity reimburses by policy generation. Roughly: 1st generation (through Sept 2009) has almost no deductible; 2nd (Oct 2009-Mar 2017) and 3rd (Apr 2017-Jun 2021) leave about 10 percent on benefits and 20 percent on non-benefits; 4th (Jul 2021-May 2026) leaves 20 percent on benefits and 30 percent on non-benefits. The 5th generation, sold from 6 May 2026, splits non-benefits into severe and non-severe: severe keeps the 30 percent coinsurance and the KRW 50,000,000 annual limit and adds a KRW 5,000,000 annual out-of-pocket cap, while non-severe raises coinsurance from 30 to 50 percent and cuts the annual limit from KRW 50,000,000 to KRW 10,000,000. No public source states which side gynecomastia falls on, so this calculator uses the 30 percent site standard; 5th-generation policyholders should confirm with their insurer.
The annual out-of-pocket ceiling applies only to NHIS benefit co-payments. However large the non-covered liposuction bill is, it never generates a ceiling refund.
For the medical expense tax credit, two separate subtractions apply, and the second one is widely missed. Income Tax Act Enforcement Decree Article 118-5(2) (promulgated 22 May 2026, effective 1 July 2026) states that the expenses in paragraph 1 "shall not include the cost of cosmetic or plastic surgery," so a cosmetic-purpose gynecomastia operation gets no credit at all. Separately, the parenthetical in Article 118-5(1) excludes "indemnity insurance benefits received," so whatever the insurer reimbursed must be subtracted from the deductible medical expense. Under Income Tax Act Article 59-4(2), the credit is 15 percent of qualifying expenses above 3 percent of gross salary, capped at KRW 7,000,000 a year.
- Ceiling: benefit co-payments only. Non-covered amounts never refund.
- Tax credit exclusion 1: cosmetic surgery is not a medical expense at all (Art. 118-5(2)).
- Tax credit exclusion 2: indemnity received is subtracted from medical expense (Art. 118-5(1)).
- Credit rate: 15 percent of the excess over 3 percent of gross salary, capped at KRW 7,000,000.
Who gets gynecomastia, and when to just wait
National Health Insurance Service data reported in Korean media put the number of patients treated for gynecomastia at 25,423 in 2020, up 63.1 percent from 15,591 in 2016 (about 13 percent a year); prevalence rose from 61 to 99 per 100,000. By age, patients in their twenties were the largest group at 8,830 (34.7 percent), followed by those in their thirties at 4,237 (16.7 percent) and those 19 and under at 3,817 (15.0 percent). HIRA big-data figures put nationwide gynecomastia surgery claims at 9,318 in 2020, 10,071 in 2021, and 11,702 in 2022.
Not every case needs surgery. The KDCA portal reports gynecomastia in 60-90 percent of newborns, 50-60 percent of adolescents (mostly ages 12-15), and 36-57 percent of older men, and states that "most are asymptomatic and resolve spontaneously within 6 to 18 months," typically disappearing "before the age of 20." Surgery is indicated when it disrupts daily life, causes severe social or psychological distress, or persists into adulthood.
Drug-induced cases may resolve on withdrawal of the causative agent. The KDCA lists alcohol, narcotics, opiates, cardiovascular drugs, tuberculosis drugs, tranquilizers, and diuretics; anabolic steroids and some hair-loss drugs are also implicated. Where hormonal disease is the cause, underlying conditions such as testicular tumor or Klinefelter syndrome must be ruled out first, since surgery without treating the cause can recur. Medical therapy with tamoxifen at 20 mg or 40 mg daily for 1-2 months is described, with hepatotoxicity and leukopenia/thrombocytopenia as possible adverse effects.
Complications and recurrence, honestly
Complication rates differ sharply by source, and the gap itself is worth knowing. Korean media citing gynecomastia surgical research report complications "from as low as 2 percent up to 25 percent." Individual clinics advertise "under 1 percent" from their own statistics. That is a 10-to-25-fold discrepancy, so when a consultation promises almost no complications, ask for the source and the definition.
Gangnam Severance Hospital states that "the most common postoperative complications are hematoma and seroma, diagnosable by a sudden increase in pain or breast size at the surgical site, and treatable by hemostasis or aspiration," and that "breast asymmetry, or recurrence of gynecomastia accompanying weight gain, may occur, in which case secondary surgery may be needed." Other reported problems include seroma over the sternum, crater-like areolar depression from over-resection or adhesion, reduced or lost nipple/areola sensation, and skin irregularity.
Recurrence is most often caused by incomplete removal of glandular and fatty tissue. Some apparent recurrence is not recurrence at all - early swelling or excessive scar tissue can make the chest look large - so judging the result immediately after surgery is premature. Because weight gain can bring gynecomastia back, weight management after surgery matters.
Insurance disputes: what has been decided
Gynecomastia is among the most disputed surgeries in Korean private indemnity. In Financial Dispute Settlement Committee decision 2016-14 (28 June 2016, KRW 990,000 in dispute, diagnosis N62), a patient who had gland excision and wound closure with one inpatient day was denied on the ground that it was "breast reduction for the purpose of improving appearance," despite the treating physician certifying it as 100 percent therapeutic. The Committee ruled for the patient, reasoning that (1) the medical literature shows gynecomastia can be a sign of serious disease such as testicular cancer and is a legitimate medical condition rather than a cosmetic matter, (2) the FSS medical adviser agreed tissue removal was medically necessary and not for appearance, and (3) HIRA materials show non-benefit treatment resulted from the surgical technique used, not from a cosmetic purpose. The conclusion: refusing reimbursement by classifying a therapeutic act as cosmetic is improper.
Denials still happen, though. Indemnity payouts for gynecomastia rose roughly fivefold in five years, from KRW 2.3 billion to KRW 10.7 billion, and insurer scrutiny tightened accordingly. In one reported case an insurer demanded Google Timeline data, CCTV, card payment records, and delivery-app history during a field investigation, then graded the patient at Simon 1 ("not requiring surgery") against the treating physician diagnosis of 2A; a joint assessment at a university hospital agreed with the insurer and the claim failed. A physician diagnosis is not the final word.
Where a denial appears unjustified, the policyholder may exercise the right to appoint a loss adjuster. In a reported case with a Simon 2B diagnosis and a KRW 6,000,000 claim, an adjuster reviewed the medical records and physician opinion, built a report around the objective severity of grade 2B and the medical basis for recommending surgery, and the insurer accepted that the operation was medically necessary rather than purely cosmetic and paid the inpatient indemnity.
The strictness has a cause. Gynecomastia has been a target of organized insurance fraud: a Financial Supervisory Service and Seoul Metropolitan Police investigation uncovered a ring that recruited about 260 fake patients at an average of KRW 8,000,000 each, taking KRW 2.1 billion in total by drawing blood during a six-hour admission and writing false gynecomastia and hyperhidrosis operative records. Legitimate patients bear the resulting scrutiny, so complete documentation is the best defense.
- Keep the ultrasound images and the measured glandular tissue size.
- Have the Simon grade, gland size in cm, and diagnosis code (N62) written on the certificate.
- Get an itemized non-covered statement separating gland excision from liposuction.
- If denied unfairly, consider exercising the loss-adjuster appointment right.
This is not the same as these other calculators
Gynecomastia is a male breast disease. Do not confuse it with the female-breast calculators on this site: the "breast reduction" option in the cosmetic surgery cost calculator is female macromastia reduction billed entirely as a non-covered cosmetic procedure; the mammotome calculator covers vacuum-assisted biopsy of female breast nodules (fibroadenoma); and the breast reconstruction calculator covers reconstruction after female breast cancer surgery.
The hyperhidrosis and osmidrosis calculator is the closest sibling because it also sits on the treatment-versus-cosmetic boundary, but there the whole operation is either covered or not. Gynecomastia is different in that gland excision and liposuction split across the benefit line within a single operation.
How to use it
Enter the tissue type, Simon grade, and glandular tissue size from your ultrasound report, plus the cause and your age. The calculator shows which of the three gates you pass, derives the surgical method, and explains why. Then set hospital level, region, inpatient days (0 for day surgery), anesthesia, upper-grade room days, indemnity generation, income decile, and gross salary.
The result separates the covered gland-excision bill from the non-covered liposuction bill, applies indemnity by generation, applies the ceiling to the covered portion only, computes the tax credit after subtracting indemnity received, and reports the final cost with an estimate range. The headline gate delta shows what passing the 2 cm and Simon 2A test is worth in money.
Note that the KDCA reports "discharge is possible on the day of surgery, and return to daily work is possible within 48 hours," so day surgery is the default; the outpatient rate (30-60 percent) then applies instead of the 20 percent inpatient rate, and the calculator lets you compare both.
This calculator is based on Korean rules (2026 National Health Insurance benefit and non-benefit billing under Annex 2 of the Rules on the Standards for National Health Insurance Benefits effective 15 April 2026, the 20 percent inpatient co-payment under Annex 2 of the Enforcement Decree of the National Health Insurance Act, the annual out-of-pocket ceiling, the Income Tax Act Article 59-4 medical expense tax credit, and the cosmetic surgery exclusion and indemnity offset in Enforcement Decree Article 118-5 paragraphs 2 and 1 effective 1 July 2026). The 2 cm glandular tissue and Simon 2A thresholds are review practice rather than statute. Figures are planning estimates, not medical advice, an insurer decision, or a hospital quote.